
ReNeuron
RENE.LReNeuron Group plc Price (RENE.L)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
57,125,960
(0.2638)%Description
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In ad... Read More
Sector: Healthcare
- Previous Close Fetching Data...
- Range $0.0-8.0
- Market Cap 1.93M
- Enterprise Value No Data
- Avg Volume Fetching Data...
- P/E Ratio Fetching Data...
- Dividend Yield Fetching Data...
Industry: Biotechnology
- ceo: Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D
- IPO Date: August, 12, 2005
- Country: GB
- Currency: GBp
- Headquaters: No Data
- Employees: 26
- Revenue from each product or segment:
Product or Segment | Value: | % - Total | Last 3Y: |
---|

- Revenue by Region
Product or Segment | Value: | % - Total | Last 3Y: |
---|
